COVID-19 Information

Public health information (CDC)

Research information (NIH)

SARS-CoV-2 data (NCBI)

Prevention and treatment information (HHS)

Español



Clinical Trials.gov

Find Studies ▼
About Studies ▼
Submit Studies ▼
Resources ▼
About Site ▼
PRS Login

History, Policies, and Laws

This page provides information on selected events, policies, and laws related to the development and expansion of ClinicalTrials.gov. It is not intended to be comprehensive.

Contents

- 1997: Congress Passes Law (FDAMA) Requiring Trial Registration
- 2000: NIH Releases ClinicalTrials.gov Web Site
- 2000–2004: FDA Issues Guidance for Industry Documents
- 2004: ClinicalTrials.gov Wins the Innovations in American Government Award
- 2005: International Committee of Medical Journal Editors Requires Trial Registration
- 2005: State of Maine Passes Clinical Studies Registration Law (Repealed in 2011)
- 2006: World Health Organization Establishes Trial Registration Policy
- 2007: Congress Passes Law (FDAAA) Expanding ClinicalTrials.gov Submission Requirements
- 2008: ClinicalTrials.gov Releases Results Database
- 2008: Declaration of Helsinki Revision Promotes Trial Registration and Results Dissemination
- 2009: Public Meeting Held at the National Institutes of Health
- 2013: European Medicines Agency <u>Expands Clinical Trial Database to Include Summary Results</u>
- 2014: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 Issued for Public Comment
- 2014: NIH Draft Policy on Registration and Results Submission of NIH-Funded Clinical Trials Issued

Mylan Exhibit 1086



×

for Public Comment

- 2015: National Cancer Institute Issues Clinical Trial Access Policy
- 2016: Final Rule for FDAAA 801 Issued
- 2016: Final NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information Issued
- 2017: Revised Common Rule (45 CFR 46) Issued
- 2020: Federal Court Decision in Seife et al. v. HHS et al., 18-cv-11462 (NRB) (S.D.N.Y. Feb. 24, 2020)

1997: Congress Passes Law (FDAMA) Requiring Trial Registration

The first U.S. Federal law to require trial registration was the Food and Drug Administration Modernization Act of 1997 (FDAMA) (PDF). Section 113 of FDAMA (FDAMA 113) required the National Institutes of Health (NIH) to create a public information resource on certain clinical trials regulated by the Food and Drug Administration (FDA). Specifically, FDAMA 113 required that the registry include information about federally or privately funded clinical trials conducted under investigational new drug applications to test the effectiveness of experimental drugs for patients with serious or life-threatening diseases or conditions.

The information in the registry was intended for a wide audience, including individuals with serious or life-threatening diseases or conditions, members of the public, health care providers, and researchers.

TO TOP

2000: NIH Releases ClinicalTrials.gov Web Site

With input from FDA and others, the NIH National Library of Medicine (NLM) developed ClinicalTrials.gov. The first version of ClinicalTrials.gov was made available to the public on February 29, 2000. At the time, ClinicalTrials.gov primarily included NIH-funded studies.

• NLM Press Release: National Institutes of Health Launches ClinicalTrials.gov (February 29, 2000)

TO TOP

2000-2004: FDA Issues Guidance for Industry Documents

In 2000 FDA issued a draft Guidance for Industry document, which provided recommendations for researchers submitting information to ClinicalTrials.gov. A final guidance document that incorporated comments from the public was issued in 2002 and was withdrawn by FDA in September 2017.

 FDA Final Guidance, March 2002: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions (Withdrawn by FDA September 2017)

In January 2004 FDA proposed a revised draft Guidance for Industry document that included guidance



for researchers submitting information required by the Best Pharmaceuticals for Children Act of 2002. This draft guidance was withdrawn by FDA in September 2017.

• FDA Draft Guidance, January 2004: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions (Withdrawn by FDA September 2017)

TO TOP

2004: ClinicalTrials.gov Wins the Innovations in American Government Award

In 2004 ClinicalTrials.gov was cited by the Ash Center for Democratic Governance and Innovation at the Harvard Kennedy School as "a successful model for the creation and maintenance of a system that processes and presents large amounts of specialized information to a wide range of users" and was selected as one of five award winners. The Innovations in American Government Awards is the Nation's preeminent program devoted to recognizing and promoting excellence and creativity in the public sector. The program highlights exemplary models of government innovation and advances efforts to address the Nation's most pressing public concerns.

- Ash Center: ClinicalTrials.gov award page
- NIH Press Release: National Institutes of Health's "ClinicalTrials.gov" Web Site Wins Prestigious Award

TO TOP

2005: International Committee of Medical Journal Editors Requires Trial Registration

In 2005 the <u>International Committee of Medical Journal Editors</u> (ICMJE) began requiring trial registration as a condition of publication.

- ICMJE Uniform Requirements for Manuscripts Submitted to Biomedical Journals: <u>Obligation to</u> Register Clinical Trials
- ICMJE: Frequently Asked Questions About Clinical Trials Registration

TO TOP

2005: State of Maine Passes Clinical Studies Registration Law (Repealed in 2011)

In 2005 the State of Maine passed a law requiring prescription drug manufacturers or labelers to submit clinical study registration and results information to ClinicalTrials.gov. The law applied to FDA-approved prescription drugs that are dispensed, administered, delivered, or promoted in Maine. In 2011 the law was repealed; it is no longer in effect.

Maine State Public Law, Chapter 461: An Act To Make Certain Prescription Drug Disclosure Laws



Consistent with Federal Law (PDF) (Repealed on July 8, 2011)

TO TOP

2006: World Health Organization Establishes Trial Registration Policy

In 2006 the World Health Organization (WHO) stated that all clinical trials should be registered, and it identified a <u>minimum trial registration dataset of 20 items</u>. In 2007 WHO launched the International Clinical Trials Registry Platform (ICTRP), which includes a <u>search portal</u> providing a single point of access to studies registered in various international registries. The ICTRP Search Portal includes data available on ClinicalTrials.gov.

• WHO: International Clinical Trials Registry Platform

TO TOP

2007: Congress Passes Law (FDAAA) Expanding ClinicalTrials.gov Submission Requirements

In 2007 the requirements for submission to ClinicalTrials.gov were expanded after Congress passed the Food and Drug Administration Amendments Act of 2007 (FDAAA) (PDF). Section 801 of FDAAA (FDAAA 801) required more types of trials to be registered; additional trial registration information; and the submission of summary results, including adverse events, for certain trials. The law also included penalties for noncompliance, such as the withholding of NIH grant funding and civil monetary penalties of up to \$10,000 a day.

- FDAAA 801 and the Final Rule
- NIH Office of Extramural Research: <u>Frequently Asked Questions</u>: FDAAA Further Resources for NIH Grantees

TO TOP

2008: ClinicalTrials.gov Releases Results Database

In September 2008, as required by FDAAA 801, ClinicalTrials.gov began allowing sponsors and principal investigators to submit the results of clinical studies. The submission of adverse event information was optional when the results database was released but was required beginning in September 2009.

• NLM Technical Bulletin: ClinicalTrials.gov to Include Basic Results Data

TO TOP

2008: Declaration of Helsinki Revision Promotes Trial Registration and Results Dissemination

In October 2008 the 59th World Medical Association (WMA) General Assembly amended the Declaration



of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Two newly added principles (paragraphs 19 and 30) considered the prospective registration and the public disclosure of study results to be ethical obligations.

In October 2013 the 64th WMA General Assembly modified these two principles. In particular, paragraph 35 (formerly 19) required prospective registration, as follows: "Every research study involving human subjects must be registered in a publicly accessible database before recruitment of the first subject."

Paragraph 36 (formerly 30) promotes the public disclosure of study results as an ethical obligation and states, in part, "Researchers have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports. All parties [i.e., researchers, authors, sponsors, editors, and publishers] should adhere to accepted guidelines for ethical reporting. Negative and inconclusive as well as positive results should be published or otherwise made publicly available."

WMA 2013 Declaration of Helsinki - Ethical Principles for Medical Research Involving Human
 Subjects

TO TOP

2009: Public Meeting Held at the National Institutes of Health

In accordance with FDAAA 801, NIH held a public meeting in April 2009 to solicit input from interested individuals about future regulations that will expand the information on ClinicalTrials.gov.

NIH gathered input on a range of issues, including the submission of adverse events information and the addition of narrative summaries to results submissions, for use in the development of draft regulations.

- NIH: Videocast and podcast of the public meeting
- Regulations.gov: <u>Docket Folder Summary: Public Meeting on Expansion of the Clinical Trial Registry and Results Data Bank</u>. Includes the meeting transcript, final meeting agenda, list of speakers for public statements, presentations, and public submissions.

TO TOP

2013: European Medicines Agency Expands Clinical Trial Database to Include Summary Results

In October 2013 the European Medicines Agency (EMA) released a new version of the European Clinical Trials Database (EudraCT), marking "the initial step of a process through which summary clinical trial results will be made publicly available through the EU CTR). "Notably, the EudraCT summary results data requirements are "substantially aligned" with those of the ClinicalTrials.gov results database.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

